InNexus Biotechnology Develops New Psoriasis Product Based On Its Skin Permeating Antibody Technology

InNexus Biotechnology Inc. (TSX.V: IXS) , a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology…